Illumina, Inc.
ILMN
株式のランク
#610
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
株価
$262.37
最終同期: 2026-10-19
時価総額
$39.62B
変化（1日）
-0.07%
変化（1年）
163.68%
国
US
取引 Illumina, Inc. (ILMN)
カテゴリー
Healthcare
Illumina, Inc.（ILMN）の利益
Jun 2026 時点の利益 TTM: $1.02B
Illumina, Inc. の最新の財務報告によると、同社の現在の利益は $1.02B です。2024 年には $-1.18B の利益を上げ、これは 2023 年の利益 $-1.12B と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Illumina, Inc. の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.02B | -6.54% |
| 2025 | $1.09B | -192.11% |
| 2024 | $-1.18B | 5.55% |
| 2023 | $-1.12B | -226.36% |
| 2022 | $884.00M | 3.27% |
| 2021 | $856.00M | -23.43% |
| 2019 | $1.12B | 25.06% |
| 2018 | $894.00M | -14.29% |
| 2017 | $1.04B | 85.92% |
| 2016 | $561.00M | -3.77% |
| 2015 | $583.00M | 29.91% |
| 2014 | $448.76M | 181.68% |
| 2013 | $159.31M | -28.43% |
| 2012 | $222.61M | 67.32% |
| 2011 | $133.05M | -28.23% |
| 2010 | $185.38M | 62.44% |
| 2009 | $114.13M | 57.01% |
| 2008 | $72.69M | -125.17% |
| 2007 | $-288.79M | -777.58% |
| 2006 | $42.62M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.61B | 649.66% |
US
|
|
| $4.76B | 369.16% |
US
|
|
| $-252.70M | -124.90% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 63.35% |
US
|
